Literature DB >> 19259283

Defining Cancer Risk in Barrett's Esophagus: A Pathologist's Perspective.

Amy E Noffsinger1.   

Abstract

Year:  2008        PMID： 19259283      PMCID： PMC2632567     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


× No keyword cloud information.
  12 in total

1.  Ki67 and p53 immunohistochemistry reduces interobserver variation in assessment of Barrett's oesophagus.

Authors:  E Lörinc; B Jakobsson; G Landberg; B Veress
Journal:  Histopathology       Date:  2005-06       Impact factor: 5.087

Review 2.  Clinical use of p53 in Barrett's esophagus.

Authors:  Rajesh N Keswani; Amy Noffsinger; Irving Waxman; Marc Bissonnette
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-07       Impact factor: 4.254

3.  Expression of alpha-methylacyl-coenzyme A racemase in dysplastic Barrett's epithelium.

Authors:  Mikhail Lisovsky; Olga Falkowski; Tawfiqul Bhuiya
Journal:  Hum Pathol       Date:  2006-09-25       Impact factor: 3.466

4.  AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease.

Authors:  Russell Dorer; Robert D Odze
Journal:  Am J Surg Pathol       Date:  2006-07       Impact factor: 6.394

5.  p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium.

Authors:  D J Wong; T G Paulson; L J Prevo; P C Galipeau; G Longton; P L Blount; B J Reid
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

6.  Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus.

Authors:  M K Hong; W B Laskin; B E Herman; M H Johnston; J J Vargo; S M Steinberg; C J Allegra; P G Johnston
Journal:  Cancer       Date:  1995-01-15       Impact factor: 6.860

7.  Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma.

Authors:  B J Reid; R C Haggitt; C E Rubin; P S Rabinovitch
Journal:  Gastroenterology       Date:  1987-07       Impact factor: 22.682

8.  Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus.

Authors:  Carlo C Maley; Patricia C Galipeau; Xiaohong Li; Carissa A Sanchez; Thomas G Paulson; Brian J Reid
Journal:  Cancer Res       Date:  2004-05-15       Impact factor: 12.701

9.  Alpha-methylacyl-CoA racemase (AMACR) immunohistochemistry in Barrett's and colorectal mucosa: only significant overexpression favours a diagnosis of intraepithelial neoplasia.

Authors:  J Sträter; C Wiesmüller; S Perner; R Kuefer; P Möller
Journal:  Histopathology       Date:  2007-12-13       Impact factor: 5.087

10.  A dietary enzyme: alpha-methylacyl-CoA racemase/P504S is overexpressed in colon carcinoma.

Authors:  Zhong Jiang; Gary R Fanger; Barbara F Banner; Bruce A Woda; Paul Algate; Karen Dresser; Jiangchun Xu; Steven G Reed; Kenneth L Rock; Peiguo G Chu
Journal:  Cancer Detect Prev       Date:  2003
View more
  1 in total

1.  Fluorescence in situ hybridization identifies high risk Barrett's patients likely to develop esophageal adenocarcinoma.

Authors:  S M Brankley; K C Halling; S M Jenkins; M R Timmer; P G Iyer; T C Smyrk; E G Barr Fritcher; J S Voss; B R Kipp; M B Campion; L S Lutzke; D M Minot; K K Wang
Journal:  Dis Esophagus       Date:  2015-06-05       Impact factor: 3.429
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.